JP2014515373A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515373A5 JP2014515373A5 JP2014512168A JP2014512168A JP2014515373A5 JP 2014515373 A5 JP2014515373 A5 JP 2014515373A5 JP 2014512168 A JP2014512168 A JP 2014512168A JP 2014512168 A JP2014512168 A JP 2014512168A JP 2014515373 A5 JP2014515373 A5 JP 2014515373A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- fumarate
- patient
- use according
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 56
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 37
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 37
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical group COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims 22
- 229960004419 dimethyl fumarate Drugs 0.000 claims 22
- 230000003902 lesion Effects 0.000 claims 10
- 239000000902 placebo Substances 0.000 claims 7
- 229940068196 placebo Drugs 0.000 claims 7
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 4
- 238000001727 in vivo Methods 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490572P | 2011-05-26 | 2011-05-26 | |
| US61/490,572 | 2011-05-26 | ||
| US201261625624P | 2012-04-17 | 2012-04-17 | |
| US61/625,624 | 2012-04-17 | ||
| PCT/US2012/039721 WO2012162669A1 (en) | 2011-05-26 | 2012-05-25 | Methods of treating multiple sclerosis and preserving and/or increasing myelin content |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014515373A JP2014515373A (ja) | 2014-06-30 |
| JP2014515373A5 true JP2014515373A5 (OSRAM) | 2015-07-16 |
Family
ID=47217796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014512168A Pending JP2014515373A (ja) | 2011-05-26 | 2012-05-25 | 多発性硬化症の治療方法およびミエリン量を保存および／または増加させる方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20140163100A1 (OSRAM) |
| EP (1) | EP2713724A4 (OSRAM) |
| JP (1) | JP2014515373A (OSRAM) |
| KR (1) | KR20140036257A (OSRAM) |
| CN (1) | CN103732062A (OSRAM) |
| AU (1) | AU2012258558A1 (OSRAM) |
| BR (1) | BR112013030169A2 (OSRAM) |
| CA (1) | CA2836480A1 (OSRAM) |
| CL (1) | CL2013003358A1 (OSRAM) |
| CO (1) | CO6811862A2 (OSRAM) |
| EA (1) | EA201391578A1 (OSRAM) |
| EC (1) | ECSP13013117A (OSRAM) |
| IL (1) | IL229448A0 (OSRAM) |
| MX (1) | MX2013013781A (OSRAM) |
| PE (1) | PE20141316A1 (OSRAM) |
| PH (1) | PH12013502443A1 (OSRAM) |
| SG (1) | SG195049A1 (OSRAM) |
| WO (1) | WO2012162669A1 (OSRAM) |
| ZA (1) | ZA201308681B (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005023241A1 (en) | 2003-09-09 | 2005-03-17 | Fumapharm Ag | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
| DK1799196T3 (en) | 2004-10-08 | 2016-08-15 | Forward Pharma As | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| EP2334378B1 (en) | 2008-08-19 | 2014-04-09 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| US9422226B2 (en) | 2011-06-08 | 2016-08-23 | Biogen Ma Inc. | Process for preparing high purity and crystalline dimethyl fumarate |
| AU2013305684B2 (en) | 2012-08-22 | 2016-11-24 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| US20140057918A1 (en) * | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of Use for Monomethyl Fumarate and Prodrugs Thereof |
| JP2015527372A (ja) | 2012-08-22 | 2015-09-17 | ゼノポート，インコーポレイティド | 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法 |
| AR094277A1 (es) | 2012-12-21 | 2015-07-22 | Biogen Idec Inc | Derivados de fumarato sustituidos con deuterio |
| PT2970101T (pt) | 2013-03-14 | 2018-10-04 | Alkermes Pharma Ireland Ltd | Pró-fármacos de fumaratos e seu uso no tratamento de várias doenças |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| EP3041467A1 (en) | 2013-09-06 | 2016-07-13 | XenoPort, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
| CN103724198A (zh) * | 2013-11-28 | 2014-04-16 | 镇江圣安医药有限公司 | 富马酸二甲酯的新型衍生物及其应用 |
| EP3110793B1 (en) | 2014-02-24 | 2019-08-21 | Alkermes Pharma Ireland Limited | Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| WO2015130998A1 (en) | 2014-02-28 | 2015-09-03 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| EP3212626B1 (en) * | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
| MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| UA122064C2 (uk) | 2014-12-11 | 2020-09-10 | Актеліон Фармасьютікалз Лтд | Схема дозування для селективного агоніста рецептора s1p1 |
| US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19721099C2 (de) * | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
| CN101056624A (zh) * | 2004-10-08 | 2007-10-17 | Adi技术制药股份公司 | 包含富马酸酯的控释药物组合物 |
| WO2007042034A1 (en) * | 2005-10-07 | 2007-04-19 | Aditech Pharma Ab | Controlled release pharmaceutical compositions comprising a fumaric acid ester |
| LT2653873T (lt) * | 2007-02-08 | 2022-10-10 | Biogen Ma Inc. | Kompozicijos ir naudojimas, skirti išsėtinei sklerozei gydyti |
| US20100130607A1 (en) * | 2007-02-08 | 2010-05-27 | Ralf Gold | Neuroprotection in demyelinating diseases |
| EP2334378B1 (en) * | 2008-08-19 | 2014-04-09 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| EP3466420A1 (en) * | 2009-04-29 | 2019-04-10 | Biogen MA Inc. | Dimethyl fumarate for the treatment of friedreich ataxia |
-
2012
- 2012-05-25 SG SG2013085667A patent/SG195049A1/en unknown
- 2012-05-25 US US14/119,373 patent/US20140163100A1/en not_active Abandoned
- 2012-05-25 EA EA201391578A patent/EA201391578A1/ru unknown
- 2012-05-25 CA CA2836480A patent/CA2836480A1/en not_active Abandoned
- 2012-05-25 EP EP12789291.7A patent/EP2713724A4/en not_active Withdrawn
- 2012-05-25 AU AU2012258558A patent/AU2012258558A1/en not_active Abandoned
- 2012-05-25 CN CN201280036988.6A patent/CN103732062A/zh active Pending
- 2012-05-25 JP JP2014512168A patent/JP2014515373A/ja active Pending
- 2012-05-25 KR KR1020137034196A patent/KR20140036257A/ko not_active Withdrawn
- 2012-05-25 WO PCT/US2012/039721 patent/WO2012162669A1/en not_active Ceased
- 2012-05-25 PE PE2013002710A patent/PE20141316A1/es not_active Application Discontinuation
- 2012-05-25 MX MX2013013781A patent/MX2013013781A/es unknown
- 2012-05-25 BR BR112013030169A patent/BR112013030169A2/pt not_active IP Right Cessation
- 2012-05-25 PH PH1/2013/502443A patent/PH12013502443A1/en unknown
-
2013
- 2013-11-14 IL IL229448A patent/IL229448A0/en unknown
- 2013-11-19 ZA ZA2013/08681A patent/ZA201308681B/en unknown
- 2013-11-22 CL CL2013003358A patent/CL2013003358A1/es unknown
- 2013-11-26 CO CO13277997A patent/CO6811862A2/es not_active Application Discontinuation
- 2013-12-26 EC ECSP13013117 patent/ECSP13013117A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014515373A5 (OSRAM) | ||
| JP2011173928A5 (OSRAM) | ||
| JP2016540738A5 (OSRAM) | ||
| JP2009102342A5 (OSRAM) | ||
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| JP2015524444A5 (OSRAM) | ||
| RU2010140682A (ru) | Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2014516942A5 (OSRAM) | ||
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| NZ714963A (en) | Compositions and methods for treating anemia | |
| NZ613291A (en) | Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof | |
| JP2013541583A5 (OSRAM) | ||
| JP2014514271A5 (OSRAM) | ||
| CN114641293A (zh) | 一种fgfr抑制剂的用途 | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| JP2012508256A5 (OSRAM) | ||
| JP2008539273A5 (OSRAM) | ||
| JP2013536837A5 (OSRAM) | ||
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2012525358A5 (OSRAM) | ||
| JP2016505050A5 (OSRAM) | ||
| WO2012042197A3 (en) | Low dose pharmaceutical composition comprising zanamivir |